Regression/Eradication of gliomas in mice by a systemically-deliverable ATF5 dominant-negative peptide

Oncotarget

Volumn 7, Issue 11, 2016, Pages 12718-12730

  Cates, Charles C ^a,d   Arias, Angelo D ^a,e   Nakayama Wong, Lynn S ^a   Lamé, Michael W ^a   Sidorov, Maxim ^a   Cayanan, Geraldine ^a   Rowland, Douglas J ^b   Fung, Jennifer ^b   Karpel Massler, Georg ^c   Siegelin, Markus D ^c   Greene, Lloyd A ^c   Angelastro, James M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California Davis   (United States)

^c Department of Medicine   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Apoptosis; ATF5; Brain cancer; Cell penetrating peptide; d n ATF5

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 5; ANTINEOPLASTIC AGENT; PLATELET DERIVED GROWTH FACTOR B; PROTEIN P53; UNCLASSIFIED DRUG; ACTIVATING TRANSCRIPTION FACTOR; ATF5 PROTEIN, MOUSE; CARRIER PROTEIN; PENETRATIN; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CANCER CELL DESTRUCTION; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG PENETRATION; GLIOBLASTOMA CELL LINE; GLIOMA; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN DOMAIN; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; DRUG DESIGN; DRUG SCREENING; HUMAN; TUMOR CELL LINE;

ACTIVATING TRANSCRIPTION FACTORS; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; DRUG DESIGN; GLIOMA; HUMANS; MICE; PEPTIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962821227     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7212     Document Type: Article

References (42)

1. Anton K, Baehring JM and Mayer T. Glioblastoma multiforme: overview of current treatment and future perspectives. Hematol Oncol Clin North Am. 2012; 26:825-853.
2. Tanaka S, Louis DN, Curry WT, Batchelor TT and Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol. 2013; 10:14-26.
3. Angelastro JM, Canoll PD, Kuo J, Weicker M, Costa A, Bruce JN and Greene LA. Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5. Oncogene. 2006; 25:907-916.
4. Arias A, Lame MW, Santarelli L, Hen R, Greene LA and Angelastro JM. Regulated ATF5 loss-of-function in adult mice blocks formation and causes regression/eradication of gliomas. Oncogene. 2012; 31:739-751.
5. Greene LA, Lee HY and Angelastro JM. The transcription factor ATF5: role in neurodevelopment and neural tumors. J Neurochem. 2009; 108:11-22.
6. Sheng Z, Li L, Zhu LJ, Smith TW, Demers A, Ross AH, Moser RP and Green MR. A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat Med. 2010; 16:671-677.
7. Dong S, Nutt CL, Betensky RA, Stemmer-Rachamimov AO, Denko NC, Ligon KL, Rowitch DH and Louis DN. Histology-based expression profiling yields novel prognostic markers in human glioblastoma. J Neuropathol Exp Neurol. 2005; 64:948-955.
8. Angelastro JM, Ignatova TN, Kukekov VG, Steindler DA, Stengren GB, Mendelsohn C and Greene LA. Regulated expression of ATF5 is required for the progression of neural progenitor cells to neurons. J Neurosci. 2003; 23:4590-4600.
9. Angelastro JM, Mason JL, Ignatova TN, Kukekov VG, Stengren GB, Goldman JE and Greene LA. Downregulation of activating transcription factor 5 is required for differentiation of neural progenitor cells into astrocytes. J Neurosci. 2005; 25:3889-3899.
10. Mason JL, Angelastro JM, Ignatova TN, Kukekov VG, Lin G, Greene LA and Goldman JE. ATF5 regulates the proliferation and differentiation of oligodendrocytes. Mol Cell Neurosci. 2005; 29:372-380.
11. Schrot RJ, Ma JH, Greco CM, Arias AD and Angelastro JM. Organotypic distribution of stem cell markers in formalin-fixed brain harboring glioblastoma multiforme. J Neurooncol. 2007; 85:149-157.
12. Lee HY, Angelastro JM, Kenney AM, Mason CA and Greene LA. Reciprocal actions of ATF5 and Shh in proliferation of cerebellar granule neuron progenitor cells. Developmental Neurobiology. 2012; 72:789-804.
13. Dluzen D, Li G, Tacelosky D, Moreau M and Liu DX. BCL-2 is a downstream target of ATF5 that mediates the prosurvival function of ATF5 in a cell type-dependent manner. The Journal of biological chemistry. 2011; 286:7705-7713.
14. Liu DX, Qian D, Wang B, Yang JM and Lu Z. p300-Dependent ATF5 Acetylation Is Essential for Egr-1 Gene Activation and Cell Proliferation and Survival. Molecular and cellular biology. 2011; 31:3906-3916.
15. Vinson CR, Hai T and Boyd SM. Dimerization specificity of the leucine zipper-containing bZIP motif on DNA binding: prediction and rational design. Genes Dev. 1993; 7:1047-1058.
16. Uekusa H, Namimatsu M, Hiwatashi Y, Akimoto T, Nishida T, Takahashi S and Takahashi Y. Cadmium interferes with the degradation of ATF5 via a post-ubiquitination step of the proteasome degradation pathway. Biochem Biophys Res Commun. 2009; 380:673-678.
17. Ciaccio NA, Reynolds TS, Middaugh CR and Laurence JS. Influence of the Valine Zipper Region on the Structure and Aggregation of the Basic Leucine Zipper (bZIP) Domain of Activating Transcription Factor 5 (ATF5). Molecular pharmaceutics. 2012; 9:3190-3199.
18. Dupont E, Prochiantz A and Joliot A. Penetratin story: an overview. Methods in molecular biology. 2011; 683:21-29.
19. Ciaccio NA, Moreno ML, Bauer RL and Laurence JS. High-yield expression in E. coli and refolding of the bZIP domain of activating transcription factor 5. Protein Expr Purif. 2008; 62:235-243.
20. Peters CS, Liang X, Li S, Kannan S, Peng Y, Taub R and Diamond RH. ATF-7, a novel bZIP protein, interacts with the PRL-1 protein-tyrosine phosphatase. J Biol Chem. 2001; 276:13718-13726.
21. Ciaccio NA and Laurence JS. Effects of Disulfide Bond Formation and Protein Helicity on the Aggregation of Activating Transcription Factor 5. Mol Pharm. 2009.
22. Assanah M, Lochhead R, Ogden A, Bruce J, Goldman J and Canoll P. Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci. 2006; 26:6781-6790.
23. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN and Holland EC. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. 2001; 15:1913-1925.
24. Hambardzumyan D, Parada LF, Holland EC and Charest A. Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia. 2011; 59:1155-1168.
25. Hesselager G, Uhrbom L, Westermark B and Nister M. Complementary effects of platelet-derived growth factor autocrine stimulation and p53 or Ink4a-Arf deletion in a mouse glioma model. Cancer Res. 2003; 63:4305-4309.
26. Jackson EL, Garcia-Verdugo JM, Gil-Perotin S, Roy M, Quinones-Hinojosa A, VandenBerg S and Alvarez-Buylla A. PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron. 2006; 51:187-199.
27. Shih AH, Dai C, Hu X, Rosenblum MK, Koutcher JA and Holland EC. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res. 2004; 64:4783-4789.
28. Uhrbom L, Hesselager G, Nister M and Westermark B. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res. 1998; 58:5275-5279.
29. Lorger M. Tumor microenvironment in the brain. Cancers. 2012; 4:218-243.
30. Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP, Johnson RS and Bergers G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell. 2003; 4:133-146.
31. Lorger M, Krueger JS, O'Neal M, Staflin K and Felding-Habermann B. Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain. Proc Natl Acad Sci U S A. 2009; 106:10666-10671.
32. Sheng Z, Evans SK and Green MR. An activating transcription factor 5-mediated survival pathway as a target for cancer therapy? Oncotarget. 2010; 1:457-460. doi: 10.18632/oncotarget.180.
33. Lindberg S, Copolovici DM and Langel U. Therapeutic delivery opportunities, obstacles and applications for cell-penetrating peptides. Ther Deliv. 2011; 2:71-82.
34. Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov Today. 2012; 17:850-860.
35. van den Berg A and Dowdy SF. Protein transduction domain delivery of therapeutic macromolecules. Current opinion in biotechnology. 2011; 22:888-893.
36. Chen A, Qian D, Wang B, Hu M, Lu J, Qi Y and Liu DX. ATF5 is overexpressed in epithelial ovarian carcinomas and interference with its function increases apoptosis through the downregulation of Bcl-2 in SKOV-3 cells. International journal of gynecological pathology. 2012; 31:532-537.
37. Fernandez P, Carretero J, Medina PP, Jimenez AI, Rodriguez-Perales S, Paz MF, Cigudosa JC, Esteller M, Lombardia L, Morente M, Sanchez-Verde L, Sotelo T and Sanchez-Cespedes M. Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations. Oncogene. 2004; 23:5084-5091.
38. Kong X, Meng W, Zhou Z, Li Y, Zhou B, Wang R and Zhan L. Overexpression of activating transcription factor 5 in human rectal cancer. Exp Ther Med. 2011; 2:827-831.
39. Monaco SE, Angelastro JM, Szabolcs M and Greene LA. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. Int J Cancer. 2007; 120:1883-1890.
40. Hu M, Wang B, Qian D, Li L, Zhang L, Song X and Liu DX. Interference with ATF5 function enhances the sensitivity of human pancreatic cancer cells to paclitaxel-induced apoptosis. Anticancer research. 2012; 32:4385-4394.
41. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J, Greiner DL and Handgretinger R. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005; 174:6477-6489.
42. Loening AM and Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003; 2:131-137.